Literature DB >> 26988410

Use of the PD-1 Pathway Inhibitor Nivolumab in a Renal Transplant Patient With Malignancy.

C L Boils1, D N Aljadir2, A W Cantafio2.   

Abstract

Entities:  

Keywords:  cancer/malignancy/neoplasia: chemotherapy; clinical research/practice; immunosuppression/immune modulation; kidney (allograft) function/dysfunction; kidney transplantation/nephrology; organ transplantation in general; rejection; signaling/signaling pathways

Mesh：

Substances：

Year:  2016        PMID： 26988410     DOI： 10.1111/ajt.13786

Source DB:  PubMed          Journal:  Am J Transplant        ISSN： 1600-6135            Impact factor:   8.086


× No keyword cloud information.
  28 in total

Review 1.  Immune checkpoint inhibitors in challenging populations.

Authors:  Douglas B Johnson; Ryan J Sullivan; Alexander M Menzies
Journal:  Cancer       Date:  2017-02-27       Impact factor: 6.860

Review 2.  Renal complications of immune checkpoint blockade.

Authors:  Naoka Murakami; Shveta Motwani; Leonardo V Riella
Journal:  Curr Probl Cancer       Date:  2016-12-19       Impact factor: 3.187

Review 3.  Current status of alloimmunity.

Authors:  Thiago J Borges; Naoka Murakami; Leonardo V Riella
Journal:  Curr Opin Nephrol Hypertens       Date:  2016-11       Impact factor: 2.894

4.  Immune Checkpoint Inhibitors and the Risk of Allograft Rejection: A Comprehensive Analysis on an Emerging Issue.

Authors:  Luis E Aguirre; Maria E Guzman; Gilberto Lopes; Judith Hurley
Journal:  Oncologist       Date:  2018-11-09

Review 5.  Liver graft rejection following immune checkpoint inhibitors treatment: a review.

Authors:  Bo Hu; Xiao-Bo Yang; Xin-Ting Sang
Journal:  Med Oncol       Date:  2019-10-11       Impact factor: 3.064

6.  Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.

Authors:  Julie R Brahmer; Christina Lacchetti; Bryan J Schneider; Michael B Atkins; Kelly J Brassil; Jeffrey M Caterino; Ian Chau; Marc S Ernstoff; Jennifer M Gardner; Pamela Ginex; Sigrun Hallmeyer; Jennifer Holter Chakrabarty; Natasha B Leighl; Jennifer S Mammen; David F McDermott; Aung Naing; Loretta J Nastoupil; Tanyanika Phillips; Laura D Porter; Igor Puzanov; Cristina A Reichner; Bianca D Santomasso; Carole Seigel; Alexander Spira; Maria E Suarez-Almazor; Yinghong Wang; Jeffrey S Weber; Jedd D Wolchok; John A Thompson
Journal:  J Clin Oncol       Date:  2018-02-14       Impact factor: 44.544

Review 7.  Cutaneous squamous cell carcinoma in the organ transplant recipient.

Authors:  Kristin Bibee; Andrew Swartz; Shaum Sridharan; Cornelius H L Kurten; Charles B Wessel; Heath Skinner; Dan P Zandberg
Journal:  Oral Oncol       Date:  2020-02-14       Impact factor: 5.337

8.  The Safety and Efficacy of Checkpoint Inhibitors in Transplant Recipients: A Case Series and Systematic Review of Literature.

Authors:  Vivek Kumar; Atul B Shinagare; Helmut G Rennke; Sandeep Ghai; Jochen H Lorch; Patrick A Ott; Osama E Rahma
Journal:  Oncologist       Date:  2020-02-11

9.  Renal allograft rejection after treatment with nivolumab in patients with metastatic renal cell carcinoma.

Authors:  Gaku Ishikawa; Takayuki Sugiyama; Toshiki Ito; Atsushi Otsuka; Hideaki Miyake
Journal:  Int Cancer Conf J       Date:  2021-01-01

10.  Pilot evaluation of PD-1 inhibition in metastatic cancer patients with a history of liver transplantation: the Mayo Clinic experience.

Authors:  Thomas T DeLeon; Marcela A Salomao; Bashar A Aqel; Mohamad B Sonbol; Raquel T Yokoda; Ahmad H Ali; Adyr A Moss; Amit K Mathur; David M Chascsa; Jorge Rakela; Alan H Bryce; Mitesh J Borad
Journal:  J Gastrointest Oncol       Date:  2018-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.